Osaka University · Faculty of Medicine / Graduate School of Medical Sciences

Research keywordshepatocellular carcinoma・HBs antigen・auranofin・atezolizumab plus bevacizumab・liver fibrosis biomarkers・MASLD・GDF15・immune cold tumors

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.2026 · Journal of gastroenterology Vol. 61 No. 1 p. 68-77 2026年1月 研究論文（学術雑誌）
• Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.2026 · PloS one Vol. 21 No. 1 2026年 研究論文（学術雑誌）
• NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.2026 · Hepatology (Baltimore, Md.) 2026年1月15日 研究論文（学術雑誌）
• Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report.2025 · Gastro hep advances Vol. 4 No. 5 p. 100634-100634 2025年 研究論文（学術雑誌）

• Official profile